Biontech wants to save the world by developing drugs without clear commercial potential
According to Biontech founders Ugur Sahin and Özlem Türeci, the value of a company will soon be measured by how they benefit society and the planet rather than revenue and bottom-line results. The two billionaires are now therefore setting their sights on malaria, tuberculosis and a number of other indications which are not obvious moneymakers.
by ulrich quistgaard, translated by catherine brett
The two founders and directors of Biontech, Ugur Sahin and Özlem Türeci, were heralded as saving the world when they were the first to get a Covid-19 vaccine developed and approved.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
In a world of options, Genmab's CEO chose partnerships
For subscribers
